AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06772415
Drug: GenSci122 tablet 250mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally Once Daily
Trial: NCT04864522
Drug: SLAMF7 FPBMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 8 weekly infusions of SLAMF7 FPBMC, then 8 additional infusions every 2 weeks.
Trial: NCT05399485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
Trial: NCT05027945
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
Trial: NCT04868877
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administrated by IV infusion
Trial: NCT05873062
Drug: AUT00201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT05873062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT05282550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 4 weeks.
Trial: NCT04167969
Drug: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
Trial: NCT05583773
Drug: ShengXian-QuYu Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 30ml/bag, given twice daily, per oral use.
Trial: NCT05039177
Drug: ERAS-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05661942
Drug: Calcium pre-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
Trial: NCT05799287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Telitacicept
Trial: NCT04695197
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
Trial: NCT05826912
Drug: Minocycline Hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
Trial: NCT05826912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 2x/day for 28 days
Trial: NCT05459142
Drug: Medical Abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Abortion
Trial: NCT04922021
Drug: LEO 138559
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 138559 is an antibody given by injection just under the skin.
Trial: NCT04922021
Drug: LEO 138559 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
Trial: NCT06779851
Drug: BPT567
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunocytokine infusion
Trial: NCT06780202
Drug: medrol dosepak
RxNorm normalized name: Medrol Dosepak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.~This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg).
Trial: NCT06780202
Drug: HYDROcodone Oral Tablet
RxNorm normalized name: hydrocodone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
Trial: NCT06781983
Drug: IPH4502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 (dose escalation) and Part 2 (dose optimization)
Trial: NCT05748366
Drug: Standard Analgesic Medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
Trial: NCT05543603
Drug: Lacer Clorhexidine 0.20% Colutorio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml 0,2% Chlorhexidine, one minute rinse
Trial: NCT05543603
Drug: Gingilacer Encías Delicadas Colutorio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
Trial: NCT05488873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Topical Solution
Trial: NCT06703177
Drug: Fluorouracil Injection
RxNorm normalized name: fluorouracil Injection
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil Injection
Trial: NCT06204432
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
Trial: NCT06299098
Drug: Matching Placebo-Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC in Part A
Trial: NCT06550362
Drug: iron sulfate
RxNorm normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral iron administration
Trial: NCT04932915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
Trial: NCT05465941
Drug: Pegylated SN-38 Conjugate PLX038
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05461352
Drug: TS-142 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received repeated doses of 5 mg of TS-142 (oral tablet)
Trial: NCT05461352
Drug: TS-142 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received repeated doses of 10 mg of TS-142 (oral tablet)
Trial: NCT05198934
Drug: Trifluridine and Tipiracil
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine and Tipiracil will be administered orally
Trial: NCT05673200
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06534125
Drug: Aromatase Inhibition Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive SOC AI therapy
Trial: NCT04913272
Drug: US-APR2020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-APR2020 capsules 45 billion CFUs of the LBT.
Trial: NCT04913272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06577181
Drug: hCG + estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotropins
Trial: NCT06440525
Drug: RSLV-132
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
Trial: NCT06440525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution
Trial: NCT06379789
Drug: REGV131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered via intravenous (IV) infusion before LNP1265
Trial: NCT06379789
Drug: LNP1265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered via IV infusion following REGV131
Trial: NCT06331559
Drug: SIM0501 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.
Trial: NCT06331559
Drug: SIM0501 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.
Trial: NCT05979857
Drug: SP-3164
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
Trial: NCT05928936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
Trial: NCT00000794
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000794
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06497439
Drug: Placebo tablet of Silfamin
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of Silfamin Placebo twice daily
Trial: NCT05272384
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05077215
Drug: EG-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Repurposed Drug
Trial: NCT04762511
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Trial: NCT05519475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection
Trial: NCT06276465
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
Trial: NCT06270147
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
Trial: NCT05897541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a tablet.
Trial: NCT05935553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * placebo capsule (for the placebo arm)~* Dosage:3 capsules of placebo per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation
Trial: NCT05539027
Drug: Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
Trial: NCT05383079
Drug: Lutetium-177 PSMA-I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
Trial: NCT06220032
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 Cycle 1-6: 750 mg/m2 (iv)
Trial: NCT06220032
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 Cycle 1-6: 50 mg/m2 (iv)
Trial: NCT06220032
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1-5 Cycle 1-6: 100 mg (oral)
Trial: NCT05645718
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by (IV) vein
Trial: NCT05645718
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by (IV) vein
Trial: NCT06601608
Drug: Herbal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosemary extract gel is used for the first time as a local drug delivery as an adjunct to non-surgical periodontal therapy in management of stage III periodontitis patients.
Trial: NCT06601608
Drug: Placebo Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo gel will be applied in deep pockets (\&gt;5mm) in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy
Trial: NCT05645718
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by (IV) vein
Trial: NCT05472090
Drug: Placebo SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Trial: NCT06017999
Drug: XG005 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
Trial: NCT06017999
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
Trial: NCT06705777
Drug: Combinations
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin combination
Trial: NCT06705686
Drug: (R)-9bMS
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
Trial: NCT06375044
Drug: SIM0500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
Trial: NCT04880642
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21
Trial: NCT04880642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05431270
Drug: Mavrostobart (PT199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.
Trial: NCT04696120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients who are assigned to placebo group will receive placebo
Trial: NCT06111313
Drug: ADT Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ADT as per standard of care (SOC).
Trial: NCT05874570
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT05874570
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT05278611
Drug: EP-9001A
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
Trial: NCT05278611
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00000175
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06458712
Drug: DSB2455
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP1 inhibitor
Trial: NCT05252884
Drug: routine postoperative calcium and calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
Trial: NCT06164613
Drug: Cinnamomum Verum oil extract
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
Trial: NCT06164613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg PO Canola oil soft gel capsule
Trial: NCT06056102
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3
Trial: NCT05828953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
Trial: NCT05225402
Drug: Hemodynamic measurements during reduction in Norepinephrine and fluid boli.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV\>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP.
Trial: NCT05136976
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 infusions of placebo at a 2 week interval.
Trial: NCT05136976
Drug: Premedications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram
Trial: NCT04333290
Drug: [11C]MeDAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiotracer
Trial: NCT05132075
Drug: JDQ443
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JDQ443 tablets, orally administered
Trial: NCT06252831
Drug: AS-Probionorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol.
Trial: NCT04923347
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI will be administered
Trial: NCT04592874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via intravenous (IV) infusion
Trial: NCT05253209
Drug: Plasmalyte A
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Plasmalyte A given for up to 48 hours
Trial: NCT05164120
Drug: Belnacasan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration